On April 29, Kangle Guard (833575) announced its 2024 annual report. The company's operating income was 890,000 yuan, a year-on-year decrease of 50.2%; the net profit attributable to the parent company changed from a loss of 301 million yuan in the same period last year to a loss of 357 million yuan, and the loss amount further expanded; the net profit attributable to the parent company after deducting non-recurring items changed from a loss of 314 million yuan in the same period last year to a loss of 363 million yuan, and the loss amount further expanded; the net operating cash flow was -125 million yuan, a year-on-year increase of 30.7%; EPS (fully diluted) was -1.2693 yuan.

In the fourth quarter, the company's operating income was 270,000 yuan, up 49.9% year-on-year; the net profit attributable to the parent company changed from a loss of 76.04 million yuan in the same period last year to a loss of 81.85 million yuan, and the loss amount further expanded; the net profit attributable to the parent company after deducting non-recurring items changed from a loss of 76.29 million yuan in the same period last year to a loss of 86.35 million yuan, and the loss amount further expanded; EPS was -0.2914 yuan.

As of the end of the fourth quarter, the company's total assets were 1.544 billion yuan, an increase of 6.2% from the end of the previous year; the net assets attributable to the parent company were 553 million yuan, a decrease of 39.1% from the end of the previous year.

The company mentioned in its 2024 annual report that there have been major changes in its business operations, especially in the progress of vaccine research and development and clinical trials. The company currently has 9 candidate vaccine products under development, of which the trivalent HPV vaccine, the nine-valent HPV vaccine (female indications) and the nine-valent HPV vaccine (male indications) have all entered the Phase III clinical stage, and the results of the relevant clinical trials are in line with expectations. In addition, the company's Phase III clinical trial of the nine-valent HPV vaccine (female indications) in Indonesia has also completed the first analysis, and the results are also in line with expectations.

In terms of industrialization, the company has built a vaccine production base in Kunming that meets the GMP standards of China, the EU and the WHO, with a designed annual production capacity of 10 million doses of trivalent HPV vaccine and 30 million doses of nine-valent HPV vaccine, and has obtained a drug production license.

https://finance.eastmoney.com/a/202504303393993758.html